This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Bente A. Somsen, Rick J.C. Schellekens, Carlo J.A. Verhoef, Michelle R. Arkin, Christian Ottmann, Peter J. Cossar, and Luc Brunsveld Journal of the American Chemical Society 2023 DOI: 10.1021/jacs.2c12781 Molecules that stabilize protein–protein interactions (PPIs) are invaluable as tool compounds for biophysics and (structural) biology, and as starting points for molecular glue drug discovery.
Previous studies show ATP-sensitive potassium (K ATP ) channel openers can reduce hypersensitivity associated with chronic pain models in rodents, and reduce morphine tolerance. Many agonists of K ATP channels are not soluble in physiologically relevant vehicles, requiring adaptation for clinical use. This study compared the antinociception activity of novel K ATP channel targeting prodrugs, CKLP1, CKLP2, and CF3-CKLP.
Formulation development, optimization and characterization of poly (lactic-co-glycolic acid) nanoparticles loaded with raloxifene by emulsion solvent diffusion evaporation technique to improve oral bioavailability by using Taguchi design. Abstract Multidrug resistance in breast cancer and the associated side-effects of anticancer therapies are significant hurdles in chemotherapy-based treatment.
Idiopathic pulmonary fibrosis , or IPF, can be a frightening diagnosis. IPF is a rare, progressive lung disease that develops differently for everyone, and managing its development can be difficult. However, some individuals are able to live with the disease and stay active for many years.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Today’s guest post comes from Rhiannon Naslund, Chief Marketing Officer at Kalderos. Rhiannon discusses the growing collaboration between manufacturers and covered entities regarding 340B discount claims. She goes on to describe the Kalderos Discount Hub solution that reviews claims that have a high likelihood of being a duplicate discount. To stay up-to-date with the latest drug discount developments, sign up for the Kalderos newsletter.
By Larry J. Bauer, Senior Regulatory Drug Expert & James E. Valentine — Incorporating patient and caregiver experiences into every phase of drug development has become increasingly prioritized during both development and review ( see, e.g. , previous coverage here ). Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision ab
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
By Larry J. Bauer, Senior Regulatory Drug Expert & James E. Valentine — Incorporating patient and caregiver experiences into every phase of drug development has become increasingly prioritized during both development and review ( see, e.g. , previous coverage here ). Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision ab
EVO dose-dependently attenuated cell viability, induced G2/M phase arrest, and apoptosis in ovarian cancer cells. EVO regulates ovarian cancer progression through the NEAT1-miR-152-3p-CDK19 axis, which further advances the possibility of EVO as a therapeutic drug for ovarian cancer. Abstract Evodiamine (EVO) has been demonstrated to promote apoptosis of ovarian cancer cells, and upregulate miR-152-3p level in colorectal cancer.
This chart shows the companies which have received the most pediatric exclusivities in the past five years. Pediatric exclusivity is granted to drug companies for conducting pediatric studies on their… The post Pharmaceutical companies with the most ‘Pediatric Exclusivity’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
I am pleased to announce our new 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Analyzes Impact of Inflation Reduction Act on U.S.
Lung cancer, the leading cause of cancer deaths in the United States , occurs when cells within the lung begin growing in an uncontrolled way, forming tumors or lesions. It typically begins in the cells lining the bronchi, and can eventually spread throughout the lung and to other parts of the body.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The COVID-19 pandemic emergency forced federal regulators to take extraordinary measures to ensure that patients were permitted continued access to important medicines. These government measures included granting temporary exemptions from certain FDA and DEA legal requirements. When the public health emergency ends on May 11, 2023 , so do these exemptions.
Employers can play a vital role in suicide prevention. Historically, suicide, mental health, and well-being have been underrepresented in workplace health and safety efforts, but this is changing. In some European countries, there are workplace standards for workplace psychosocial hazards that put workers at risk for suicide. Additionally, in France, employers have been made accountable for toxic workplaces and management practices that contributed to worker suicides.[1] Some of the latest workp
Informa Connect’s Medicaid & Government Pricing Congress May 16-18, 2023 in Washington, DC www.informaconnect.com/medicaid2023 Drug Channels readers save 10% with code 23DRCH10 * Join the life science industry on May 16-18, 2023 in Washington, DC at the Medicaid & Government Pricing Congress to conquer complex Medicaid regulatory guidelines and evolve strategies to contract, report and comply with federal and state healthcare programs.
Smaller clinical trials can be optimized in significant ways using simulation-guided design. A small biotech studying chronic pain had a one-year trial it planned to implement, but wondered if it could be shortened. Let’s take a closer look at how Cytel helped this sponsor reduce their trial time without sacrificing power.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
By Véronique Li, Senior Medical Device Regulation Expert — Earlier this month, FDA published a final rule to update the mammography regulations, issued under the Mammography Quality Standards Act of 1992 (MQSA) and the Federal Food, Drug, and Cosmetic Act (FD&C Act). The MQSA was passed to ensure, among other things, that nationwide, patients have access to quality mammography services.
Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8 billion raised by their spinout and startup portfolio Read more about the collaboration here.
Moving research from concept to market is like conducting a symphony — there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project. As research continues to speed up and span across disciplines, the challenge of bringing new ideas and innovations from the academic sphere to the commercial realm becomes increasingly crucial.
This chart shows the drugs with the most patents in Colombia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Colombia? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Before any new medication, therapy, or treatment is put onto the market, it must first be approved by the Food and Drug Administration. Part of this approval process is thorough testing through clinical trials to ensure that any therapy is safe and effective before it is released to the general public.
Proteomic profiling is an important aspect of cancer research and drug development. It provides protein abundance information that complements genomics data from next-generation sequencing (NGS).
The moment you decide which DrugBank license or products best suit your needs isn’t the final step in our relationship, it is just the beginning. And from our perspective, it’s also the most exciting part because we get to dig into your goals and connect you with a whole team of support professionals who can help you get where you need to be.
Annual Drug Patent Expirations for SUMAVEL+DOSEPRO Sumavel Dosepro is a drug marketed by Endo Ventures Ltd and is included in one NDA. There are nine patents protecting this drug. SUMAVEL… The post New patent expiration for Endo Ventures drug SUMAVEL DOSEPRO appeared first on DrugPatentWatch - Make Better Decisions.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Recently, we included a Natural Product-likeness score for chemical compounds stored in ChEMBL. We made use of an algorithm published by Peter Ertl, Silvio Roggo and Ansgar Schuffenhauer in 2008. Whereas the original version of this algorithm used a commercial data set of Natural Product molecules for training the algorithm (the CRC Dictionary of Natural Products) and an in-house library of synthetic molecules as a negative set, we used Greg Landrum's RDKit implementation which is based on ~50,0
Maintaining regulatory compliance at research sites and institutions is no small feat – documents need to be updated and maintained in a consistent manner to ensure compliance. While regulatory management can take significant time and effort, utilizing an eRegulatory system can help staff increase productivity, improve compliance, and save money. Advarra’s eRegulatory Management System (eReg) is designed to adapt to and streamline research site regulatory workflows.
Many industries have long since adopted the practice of modeling and simulating experimental scenarios. And despite initial hesitancy in the clinical trials space, simulation-guided design has revolutionized, and will continue to transform, the landscape of clinical trial development. We are already seeing incredible gains in productivity, efficiency, and in our ability to ask and answer increasingly more complex and novel questions.
Annual Drug Patent Expirations for VYXEOS Vyxeos is a drug marketed by Celator Pharms and is included in one NDA. It is available from one supplier. There are nine patents… The post New patent for Celator Pharms drug VYXEOS appeared first on DrugPatentWatch - Make Better Decisions.
For researchers who are developing or working with analytical procedures, the new ICH Q14 Analytical Procedure Development and revised ICH Q2(R2) Validation of Analytical Procedures drafts represent foundational guidance documents. Together, they describe suggested development and validation activities for the lifecycle of an analytical procedure used to assess the quality of drug substances and drug products.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
130 
Let's personalize your content